Preprint identifies NuA4 subunit overexpression as a suppressor of H3K36M oncohistone growth defects in yeast

A preprint posted to bioRxiv reports work conducted in budding yeast to investigate the molecular consequences of the H3K36M oncohistone — a recurrent histone H3 mutation, first identified in human cancers including chondroblastoma and certain paediatric midline gliomas, in which lysine 36 is substituted by methionine.

H3K36M acts in a dominant-negative fashion, inhibiting the methyltransferases that normally deposit methyl marks at H3K36 and thereby disrupting chromatin-based regulation of gene expression. Understanding which cellular pathways can compensate for or suppress these effects is of interest for cancer biology, though the yeast system used here is a model organism context rather than a direct therapeutic study.

The authors previously identified Eaf1 — the catalytic subunit of the NuA4 lysine acetyltransferase complex — as a relevant factor. The current preprint reports that overexpression of Eaf1 rescues the growth defects associated with H3K36M expression in yeast, and that this rescue operates through increased acetylation of the histone H4 tail. The work adds mechanistic detail to understanding how histone modification pathways interact in the context of oncohistone-driven chromatin dysregulation.

As a bioRxiv preprint, the findings have not yet undergone peer review. Histone H3 shares approximately 90% sequence identity between budding yeast and humans, supporting the use of this model. The work is primarily of interest to researchers in chromatin biology, cancer epigenomics, and histone modification pathways.